Safety and Efficacy of Faricimab in Patients With NPDR
Status:
Not yet recruiting
Trial end date:
2026-03-23
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2 study is comprised of two groups to evaluate the safety,
tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic
Retinopathy.